We could not find any results for:
Make sure your spelling is correct or try broadening your search.
GSK PLC 24 September 2024 Issued: 24 September 2024, London UK GSK's Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion ...
GSK PLC on Wednesday said it reached two confidential settlements regarding the Zantac case in California State Court ...
GSK PLC 18 September 2024 Issued: 18 September 2024, London UK Statement: Zantac (ranitidine) litigation - Russell and Hughes cases GSK plc (LSE/NYSE: GSK) today confirmed it has...
GSK PLC on Tuesday said its Blenrep cancer treatment will undergo review in Japan after successful authorisations rec ...
GSK PLC 17 September 2024 Issued: 17 September 2024, London UK Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma accepted for regulatory review in Japan...
Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk PR Newswire PHILADELPHIA, Sept. 16, 2024 Brooke Shields convenes other celebrities, influencers and...
GSK PLC on Friday announced that it has been granted breakthrough therapy designation in China for Blenrep, a treatme ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -119 | -7.23404255319 | 1645 | 1649 | 1522.5 | 11326817 | 1571.32025915 | DE |
4 | -81.5 | -5.0699844479 | 1607.5 | 1678 | 1522.5 | 7536132 | 1618.89039609 | DE |
12 | 10.5 | 0.692840646651 | 1515.5 | 1678 | 1485.5 | 6824486 | 1568.63848056 | DE |
26 | -157 | -9.32857991682 | 1683 | 1820 | 1484 | 7239951 | 1621.75297629 | DE |
52 | 3.8 | 0.249638680857 | 1522.2 | 1820 | 1376 | 7581602 | 1579.24826715 | DE |
156 | 114.2 | 8.08896444256 | 1411.8 | 1824.4 | 1283.2 | 8596626 | 1535.59136696 | DE |
260 | -168 | -9.9173553719 | 1694 | 1857 | 1190.8 | 8794728 | 1523.32611015 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions